Following this strategy, we have previously developed dual modulators to target, for example, farnesoid X receptor (FXR) and soluble epoxide hydrolase (sEH),[6, 7, 8] or FXR and peroxisome proliferator‐activated receptors (PPARs).[9, 10] Strong therapeutic efficacy of such multi‐target agents in preclinical NASH models[10, 11] corroborates the potential of designed polypharmacology in this indication. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.